Neumentum announced agreement with Janssen Pharmaceutica NV and McNeil Consumer Pharmaceuticals Co.

Agreement significantly expands Neumentum's pipeline of investigational pain therapies aimed at addressing the growing need for innovative analgesics

Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated, today announced it has entered into a global licensing agreement with Janssen Pharmaceutica NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies, for the rights to a novel oral analgesic, JNJ-10450232, plus a portfolio of backup compounds.

JNJ-10450232 is neither an opioid nor an NSAID. The target indication for JNJ-10450232 is for moderate to moderately severe acute pain. Phase 2A clinical studies have been completed for this compound. If successfully developed through additional clinical trials, and if ultimately approved by FDA, this portfolio of compounds may provide new options for pain relief.

"By strategically expanding our pipeline, Neumentum will be well positioned to address patients' and providers' needs for acute pain relief in both hospital and community settings, with both IV and oral non-opioid products", said Scott Shively, chief executive officer of Neumentum. "There is a real lack of innovation in the pain management space, despite a growing need for new options that are safe and effective."

"We are committed to exploring the potential of these compounds, which we believe are unique," said Joseph Pergolizzi, M.D., executive chairman of Neumentum.

This deal complements Neumentum's existing portfolio, particularly the company's lead product candidate, NTM-001. NTM-001 is a novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous infusion that is in development for the short-term management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting, for up to 24 hours.

Information source: here